<DOC>
	<DOCNO>NCT00084812</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , work different way stop tumor cell divide stop grow die . Safingol may stop growth tumor cell block enzymes necessary growth stop blood flow tumor . PURPOSE : This phase I trial study side effect best dose safingol give cisplatin treat patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Safingol Cisplatin Treating Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) safingol administer cisplatin patient locally advance metastatic solid tumor . Secondary - Determine toxic effect regimen patient . - Determine clinical pharmacokinetics regimen patient . - Determine , preliminarily , therapeutic activity regimen patient . - Determine safe dose ( i.e. , near MTD ) phase II evaluation regimen patient . - Determine , preliminarily , role ceramide S1P , relative response apoptosis , patient treat regimen . OUTLINE : This open-label , non-randomized , dose-escalation study safingol . Patients receive safingol IV 1 hour cisplatin IV 1 hour day 1 . Courses repeat every 21 days* absence disease progression unacceptable toxicity . NOTE : *Patients receive safingol day 1 8 cisplatin day 8 course 1 ; course 1 28 day duration . Cohorts 3-6 patient receive escalate dos safingol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient treat dose level .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Safingol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Locally advance metastatic disease Refractory standard therapy OR amenable standard therapy No known CNS metastasis CNS primary PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy At least 12 week Hematopoietic Neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC count ≥ 3,500/mm^3 Hemoglobin ≥ 9.5 g/dL Haptoglobin ≥ 30 mg/dL No concurrent hemolysis history nondruginduced hemolysis ( e.g. , spherocytosis ) Hepatic AST ALT ≤ 2.5 time upper limit normal Bilirubin ≤ 1.5 mg/dL PT PTT normal Renal Creatinine ≤ 1.5 mg/dL Cardiovascular No cardiac arrhythmias No congestive heart failure No myocardial infarction within past 6 month Other Not pregnant Negative pregnancy test No nursing least 2 month study participation Fertile patient must use effective contraception least 2 month study participation HIV negative No mental incapacity would preclude give informed consent No moderatetosevere highfrequency hear loss No persistent severe ( grade 2 ) druginduced peripheral neuropathy No known allergy cisplatin platinumcontaining compound No serious uncontrolled infection No medical condition reason would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior immunotherapy Chemotherapy Prior cisplatin allow At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy Surgery Not specify Other Recovered prior therapy No concurrent vitamin , antioxidant , herbal preparation , supplement Concurrent single tablet multivitamin allow No concurrent investigational medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>